1
Return

Glycolytic reprogramming in precancerous lesions of gastric cancer progression: pathogenesis and therapeutic potential

delete2026-08-13
delete0
delete
OA
AI
S
SN Siying Niu
H
HS Heyuan Sun
Z
ZW Zijian Wang
Q
QJ Qiuyu Jin
Z
ZS Zhiwen Sun
D
DY Dongyang Yu
Y
YZ Yang Zhang *
DOI:10.3389/fonc.2026.1885113delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Precancerous lesions of gastric cancer (PLGC) represent a critical stage preceding the development of gastric cancer. Their progression to gastric cancer remains a significant challenge in clinical prevention and treatment. Recent studies have shown that glycolytic reprogramming is a dynamic and modifiable metabolic process in PLGC. It may emerge during the progression of PLGC and contribute to the pathological remodeling of the gastric mucosa. This article reviews the stage-specific characteristics; pathogenesis; and therapeutic potential of glycolytic reprogramming in PLGC. During the progression of PLGC; glycolytic activity may be activated early on; diminish during the glandular atrophy stage; and be reactivated during intestinal metaplasia (IM); dysplasia; and spasmolytic polypeptide-expressing metaplasia (SPEM). Key regulatory factors include Helicobacter pylori (H. pylori) infection; the PI3K/Akt/mTOR-HIF-1α axis; glucose uptake mediated by glucose transporters (GLUTs); microRNAs (miRNAs); the p53/TIGAR pathway; and p57. These metabolic alterations may promote PLGC progression through an imbalance between proliferation and apoptosis; lactate accumulation; and the formation of an acidic microenvironment. Intervention strategies targeting glycolytic reprogramming may offer potential approaches for metabolic intervention in PLGC. These strategies include traditional Chinese medicine formulations; natural bioactive compounds; and glycolysis inhibitors derived from gastric cancer research.
Keywords:
molecular mechanisms
metabolic intervention
precancerous lesions of gastric cancer
glycolytic reprogramming
pathological progression

Journal

Frontiers in Oncology cover
Frontiers in Oncology
IF:
3.3
Papers:
3.4W
Citations:
9.5W

Organization

G
graduate college
Scholars:
13
Papers: 10
Citations: 0
D
Department of Gastroenterology
Scholars:
3.0K
Papers: 1.1K
Citations: 3
Cited Papers

Cited Papers

Citing Papers

Citing Papers